MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MEIP
CUSIPN/A
Phone858-369-7100
Debt
Debt-to-Equity RatioN/A
Current Ratio13.24
Quick Ratio13.24
Price-To-Earnings
Trailing P/E Ratio-5.07
Forward P/E Ratio-6.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.62 million
Price / Sales164.61
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book5.21
Profitability
EPS (Most Recent Fiscal Year)($0.74)
Net Income$-40,060,000.00
Net Margins-2,470.28%
Return on Equity-67.76%
Return on Assets-47.93%
Miscellaneous
Employees32
Outstanding Shares71,110,000
Market Cap$285.88 million
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) released its quarterly earnings results on Thursday, August, 30th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.14. The business earned $0.55 million during the quarter, compared to analyst estimates of $0.46 million. MEI Pharma had a negative return on equity of 67.76% and a negative net margin of 2,470.28%. View MEI Pharma's Earnings History.
When is MEI Pharma's next earnings date?
What price target have analysts set for MEIP?
6 Wall Street analysts have issued 12 month price objectives for MEI Pharma's stock. Their forecasts range from $7.00 to $12.00. On average, they expect MEI Pharma's share price to reach $8.10 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price. View Analyst Price Targets for MEI Pharma.
What is the consensus analysts' recommendation for MEI Pharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. Cann analysts commented, "We currently anticipate ME-401 being filed with FDA in 2021 and that the drug could launch in 2022 with sales of $620.6 million by 2023. The collaboration with BeiGene, to study ME-401 in combination with zanubrutnib, could result in data that expands ME-401’s potential use beyond our current outlook. The results of the phase Ib study, presented at 2018 ASCO, were very impressive, with ORR of 90%. In addition to these data, we believe the combination studies with rituximab and with zanubrutinib could expand the number of addressable patients for ME-401. ME-401 is one of four development stage assets in MEI Pharma’s portfolio and is the second most advanced." (10/11/2018)
- 2. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (7/18/2018)
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include CannTrust (CNTTF), Uniqure (QURE), Kiniksa Pharmaceuticals (KNSA), Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Rhythm Pharmaceuticals (RYTM), Zai Lab (ZLAB), Lexicon Pharmaceuticals (LXRX), Athenex (ATNX), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Radius Health (RDUS), Aptinyx (APTX) and Akorn (AKRX).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold, CEO, Pres & Director (Age 64)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 57)
- Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 54)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 64)
- Mr. David A. Walsey, VP of IR & Corp. Communications
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $3.75.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $285.88 million and generates $1.62 million in revenue each year. The company earns $-40,060,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.
What is MEI Pharma's official website?
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
